Neuronetics Stock Price, News & Analysis

Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company in the surgical and medical instrument manufacturing industry. According to company disclosures, Neuronetics focuses on designing, developing, and marketing products intended to improve the quality of life for patients who suffer from neurohealth and psychiatric disorders. The company describes a strategic vision of transforming the lives of patients whenever and wherever they need help, using what it characterizes as leading neurohealth therapies.

Neuronetics is closely associated with NeuroStar Advanced Therapy, a non-drug, noninvasive, office-based treatment that uses transcranial magnetic stimulation (TMS). The Polygon company description and multiple Neuronetics press releases state that the NeuroStar Advanced Therapy System creates pulsed, MRI-strength magnetic fields designed to stimulate specific areas of the brain associated with mood. The company positions NeuroStar Advanced Therapy as a non-invasive therapeutic alternative for patients with major depressive disorder (MDD) when traditional medication has not provided satisfactory improvement.

Neuronetics reports that NeuroStar Advanced Therapy is cleared by the U.S. Food and Drug Administration for several indications. These include treatment of depressive episodes in adults with MDD who have not achieved satisfactory improvement from previous antidepressant medication in the current episode, decreasing anxiety symptoms in adult patients with MDD who may exhibit comorbid anxiety symptoms (anxious depression), and use as an adjunct for adults with obsessive-compulsive disorder. The therapy is also cleared as a first-line adjunct for the treatment of MDD in adolescent patients aged 15–21. These regulatory clearances are central to the company’s positioning in the neurohealth and mental health treatment market.

In addition to manufacturing and selling the NeuroStar Advanced Therapy System and associated treatment sessions, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States. Company press releases explain that these centers offer NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. Greenbrook treatment centers also offer SPRAVATO (esketamine) Nasal Spray, which Neuronetics describes as a prescription medicine indicated for treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant, and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Neuronetics reports that Greenbrook has delivered more than one million treatments to tens of thousands of patients struggling with depression, based on the ranges disclosed in its news releases.

The company repeatedly characterizes itself as a global leader in neuroscience and emphasizes that it delivers in-office treatments through NeuroStar Advanced Therapy that can improve quality of life for people suffering from neurohealth conditions when traditional medication has not helped. Neuronetics highlights that NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, citing millions of treatment sessions delivered and what it describes as the largest clinical data set and the world’s largest depression outcomes registry for a TMS treatment system for depression. These statements underscore the company’s focus on evidence-based, device-driven mental health therapies.

Neuronetics’ business model, as described in its press releases and SEC filings, combines medical device manufacturing with healthcare service delivery. Revenue sources identified by the company include sales of NeuroStar Advanced Therapy Systems, treatment sessions, and clinic revenue generated by Greenbrook treatment centers. The company’s SEC filings further describe it as vertically integrated following its acquisition of Greenbrook TMS Inc., with U.S. clinic revenue reported as a distinct category alongside system and treatment session revenue. This integration links the company’s device platform with a network of treatment centers that use those devices in clinical practice.

From a regulatory and capital markets perspective, Neuronetics’ common stock trades on The Nasdaq Global Market under the symbol STIM, as noted in its Form 8-K filings. These filings also indicate that the company uses credit facilities and equity offerings to support its operations and growth initiatives. For example, Neuronetics has described amendments to its credit agreement with Perceptive Credit Holdings IV, LP that provide additional borrowing capacity and adjust liquidity requirements, and it has disclosed the use of at-the-market equity offerings to raise capital for general corporate purposes.

Neuronetics is headquartered in Malvern, Pennsylvania, according to its SEC filings, which list Malvern and the associated ZIP code as the location of its principal offices. The company’s disclosures and press releases consistently emphasize a belief that mental health is as important as physical health and describe a commitment to expanding access to advanced mental health therapies. This includes working with payors and health policy stakeholders. Neuronetics notes that it is the only TMS company in its industry with a dedicated health policy team that partners with providers and payors to advocate for health policy updates, including coverage decisions for TMS therapy.

The company’s communications also highlight payer coverage milestones and partnerships that are relevant to its operating environment. For example, Neuronetics has announced expanded coverage for NeuroStar TMS therapy by New York State Medicaid for adults with MDD and by TRICARE West for adolescents aged 15 and older. It has also described exclusive agreements, such as a three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network’s locations and uses the Greenbrook platform to provide fee-based operational and patient-support services.

Neuronetics’ SEC filings and press releases further indicate that the company monitors and reports on the number of patients treated and treatment sessions delivered using NeuroStar TMS. Milestones cited include hundreds of thousands of global patients and several million treatment sessions. The company also references real-world clinical data drawn from its NeuroStar outcomes databases, including data published in peer-reviewed journals on the effectiveness of NeuroStar TMS in adolescents and young adults with MDD.

For investors and analysts evaluating STIM stock, Neuronetics represents a medical technology issuer at the intersection of device manufacturing and behavioral health services. Its disclosures emphasize the importance of regulatory clearances, payer coverage, clinical evidence, and the integration of its device platform with owned and affiliated treatment centers. The company’s SEC filings, including periodic reports and current reports on Form 8-K, provide additional detail on its financial performance, capital structure, and material agreements.

Business segments and activities

Based on the company’s own categorizations in its financial reporting, Neuronetics’ activities can be viewed across several primary areas:

• NeuroStar Advanced Therapy System: Design, development, and sale of the TMS system used to deliver NeuroStar Advanced Therapy in clinical settings.
• Treatment sessions: Sale of treatment sessions associated with the NeuroStar system, as reported in its U.S. revenues by product category.
• Clinic revenue: Revenue generated by Greenbrook treatment centers in the United States, which provide NeuroStar TMS, SPRAVATO, and other modalities for MDD and other mental health disorders.
• Health policy and payer engagement: Activities by a dedicated health policy team that works with providers and payors to support coverage and reimbursement for TMS therapy.

Regulatory and clinical context

Neuronetics’ disclosures emphasize that the NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for specific indications in adult and adolescent populations. The company also references a large outcomes registry and clinical data sets that support the use of NeuroStar TMS in depression, including adolescents and young adults. These elements are central to how Neuronetics presents its role in the mental health treatment landscape.

Stock and corporate information

Neuronetics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Global Market under the ticker symbol STIM, as confirmed in multiple Form 8-K filings. These filings also identify Malvern, Pennsylvania as the location of the company’s principal offices. Neuronetics uses current reports on Form 8-K to communicate material events, such as financial results, executive appointments, credit facility amendments, and leadership transition plans.

Frequently asked questions about Neuronetics, Inc. (STIM)

What does Neuronetics, Inc. do?
According to its press releases and SEC filings, Neuronetics is a commercial stage medical technology and healthcare company focused on designing, developing, and marketing products that improve the quality of life for patients with neurohealth and psychiatric disorders. Its primary product platform is the NeuroStar Advanced Therapy System, a non-drug, noninvasive TMS treatment used in office-based settings.

What is NeuroStar Advanced Therapy?
Company materials describe NeuroStar Advanced Therapy as a non-invasive, non-systemic treatment that uses transcranial magnetic stimulation to create pulsed, MRI-strength magnetic fields that induce electrical currents intended to stimulate specific brain areas associated with mood. It is cleared by the U.S. Food and Drug Administration for certain indications in adults and adolescents with major depressive disorder and for adjunctive use in obsessive-compulsive disorder.

How does Neuronetics generate revenue?
Neuronetics’ financial disclosures identify revenue from sales of the NeuroStar Advanced Therapy System, associated treatment sessions, and clinic revenue from Greenbrook treatment centers in the United States. SEC filings present these as separate categories within U.S. revenues by product category.

What is Greenbrook TMS Inc. and how is it related to Neuronetics?
Greenbrook TMS Inc. is a network of treatment centers in the United States that Neuronetics describes as operating under its ownership. These centers offer NeuroStar Advanced Therapy for MDD and other mental health disorders and also provide SPRAVATO Nasal Spray. Neuronetics’ press releases state that Greenbrook treatment centers have delivered more than one million treatments to tens of thousands of patients with depression.

Where is Neuronetics headquartered?
Neuronetics’ Form 8-K filings list Malvern, Pennsylvania as the location associated with the company’s principal offices, along with a corresponding ZIP code.

On which exchange does STIM trade?
Neuronetics’ common stock is listed on The Nasdaq Global Market under the ticker symbol STIM, as indicated in its SEC filings.

What conditions is NeuroStar TMS cleared to treat?
Company disclosures state that the NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with major depressive disorder who have not achieved satisfactory improvement with prior antidepressant medication, to decrease anxiety symptoms in adult patients with MDD who may exhibit comorbid anxiety symptoms, as an adjunct for adults with obsessive-compulsive disorder, and as a first-line adjunct for MDD in adolescent patients aged 15–21.

How does Neuronetics describe its position in neuroscience and TMS?
Neuronetics’ press releases describe the company as a global leader in neuroscience and state that NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults. The company supports these statements by citing millions of treatments delivered and what it identifies as the largest clinical data set and outcomes registry for a TMS treatment system for depression.

Does Neuronetics engage with payors and health policy?
Yes. Neuronetics notes that it is the only TMS company in its industry with a dedicated health policy team that works with providers and payors to advocate for health policy updates, including coverage decisions for TMS therapy. The company has highlighted coverage expansions by New York State Medicaid and TRICARE West for NeuroStar TMS in specific patient populations.

What types of corporate events does Neuronetics report in SEC filings?
Neuronetics uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements, leadership changes including executive appointments and planned CEO retirement, and investor presentations. These filings also reiterate its stock listing on The Nasdaq Global Market under the symbol STIM.